Tracking Real-Life use of a common IBD treatment

NCT ID NCT05633771

Ongoing Disease control Sponsor: Sandoz Source: ClinicalTrials.gov ↗

Summary

This study aims to see how long patients with Crohn's disease or ulcerative colitis (collectively called IBD) continue using the biosimilar medication Hyrimoz in real-world doctor's offices. Researchers will follow over 500 patients for up to a year to see if they stay on the treatment, how satisfied they are, and how well their disease is controlled. The study is observational, meaning it watches and records what happens in normal medical practice without changing any treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Sandoz Investigational Site Belgium

Aalst, Belgium
Sandoz Investigational Site Belgium

Antwerp, Belgium
Sandoz Investigational Site Belgium

Bonheiden, Belgium
Sandoz Investigational Site Belgium

Brussels, Belgium
Sandoz Investigational Site Belgium

Eeklo, Belgium
Sandoz Investigational Site Belgium

Ghent, Belgium
Sandoz Investigational Site Belgium

Herentals, Belgium
Sandoz Investigational Site Belgium

Kortrijk, Belgium
Sandoz Investigational Site Belgium

Liège, Belgium
Sandoz Investigational Site Belgium

Namur, Belgium
Sandoz Investigational Site Belgium

Seraing, Belgium
Sandoz Investigational Site Belgium

Sint-Niklaas, Belgium
Sandoz Investigational Site Belgium

Tongeren, Belgium
Sandoz Investigational Site France

Amiens, France
Sandoz Investigational Site France

Auxerre, France
Sandoz Investigational Site France

Bayonne, France
Sandoz Investigational Site France

Beauvais, France
Sandoz Investigational Site France

Brest, France
Sandoz Investigational Site France

Caen, France
Sandoz Investigational Site France

Castelnau-le-Lez, France
Sandoz Investigational Site France

Clermont-Ferrand, France
Sandoz Investigational Site France

Clichy, France
Sandoz Investigational Site France

Cornebarrieu, France
Sandoz Investigational Site France

Créteil, France
Sandoz Investigational Site France

Gien, France
Sandoz Investigational Site France

Le Coudray, France
Sandoz Investigational Site France

Le Kremlin-Bicêtre, France
Sandoz Investigational Site France

Lille, France
Sandoz Investigational Site France

Lyon, France
Sandoz Investigational Site France

Marseille, France
Sandoz Investigational Site France

Montpellier, France
Sandoz Investigational Site France

Nancy, France
Sandoz Investigational Site France

Neuilly-sur-Seine, France
Sandoz Investigational Site France

Nice, France
Sandoz Investigational Site France

Nîmes, France
Sandoz Investigational Site France

Orléans, France
Sandoz Investigational Site France

Paris, France
Sandoz Investigational Site France

Pessac, France
Sandoz Investigational Site France

Pierre-Bénite, France
Sandoz Investigational Site France

Poitiers, France
Sandoz Investigational Site France

Pringy, France
Sandoz Investigational Site France

Reims, France
Sandoz Investigational Site France

Rennes, France
Sandoz Investigational Site France

Saint-Etienne, France
Sandoz Investigational Site France

Saint-Nazaire, France
Sandoz Investigational Site France

Sarrebourg, France
Sandoz Investigational Site France

Toulouse, France
Sandoz Investigational Site France

Tours, France
Sandoz Investigational Site France

Troyes, France
Sandoz Investigational Site France

Vandœuvre-lès-Nancy, France
Sandoz Investigational Site France

Vénissieux, France

Conditions

Explore the condition pages connected to this study.

INFLAMMATORY BOWEL DISEASE